GlySens Incorporated is dedicated to advancing diabetes care through the development of a long-term, implantable continuous glucose monitoring technology. Their flagship product, the Eclipse 3 CGM System, is a fully implantable device that lasts for years, unlike traditional CGM devices. The device continuously measures and transmits glucose readings to the user's phone, offering seamless connectivity to insulin pumps and other health applications. GlySens employs innovative technology, including oxygen-based glucose sensing and multi-channel array detectors, to ensure accurate and long-lasting glucose monitoring. The company's focus is on empowering individuals with worry-free diabetes technologies for optimized care and improved quality of life.